Annexon Inc
NASDAQ:ANNX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Annexon Inc
NASDAQ:ANNX
|
US |
|
E
|
Enterprise Metals Ltd
F:RM9
|
AU |
|
DFI Retail Group Holdings Ltd
F:DFA1
|
HK |
|
New Wave Holdings Ltd
SGX:5FX
|
SG |
|
S
|
Sanofi SA
BMV:SNYN
|
FR |
|
F
|
Fresenius SE & Co KGaA
XMUN:FRE
|
DE |
|
Sanofi SA
OTC:SNYNF
|
FR |
|
S
|
Sanofi SA
DUS:SNW
|
FR |
|
M
|
Microsoft Corp
F:MSF
|
US |
Intrinsic Value
Is ANNX undervalued or overvalued?
See the intrinsic value estimate for
Annexon Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Annexon Does
Annexon is a biotechnology company that develops antibody medicines aimed at turning down harmful immune system activity. Its lead idea is to block C1q, a protein that helps start the classical complement pathway, which can drive inflammation and tissue damage in certain diseases. The company is focused on treatments for autoimmune, neurological, and eye disorders where too much immune activation can make patients worse.
- Headquarters
- United States of America US
- Employees
- 96
- IPO date
- Jul 24, 2020
Revenue & Expenses Breakdown
Annexon Inc
Earnings Waterfall
Annexon Inc
The intrinsic value for
Annexon Inc (ANNX) under the Base Case is hidden USD.
Compared with the current market price of 4.32 USD, the stock appears hidden.